The clinical effectiveness of 311C90 in the acute treatment of migraine.
Efficacy with currently marketed antimigraine compounds is less than optimal. 311C90 is a novel and selective 5-HT1D receptor agonist in development for the acute treatment of migraine. It shows evidence of both central and peripheral activity within the trigemino-vascular system and it is rapidly absorbed following oral administration. In clinical studies in migraine patients, a headache response at 2 hours has been observed in 65-81% of patients at doses above 1 mg. Favourable response rates are reported as early as 1 hour post-dose and efficacy rates continue to improve up to 4 hours. Headache recurrence is reported by 25-35% of patients and 311C90 is also effective in relieving the non-headache symptoms of migraine.
Ferrari
M D
MD
Department of Neurology, Leiden University Hospital, The Netherlands.
D004311:Double-Blind Method; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D015337:Multicenter Studies as Topic; D010080:Oxazoles / Q000627:therapeutic use*; D023303:Oxazolidinones; D016032:Randomized Controlled Trials as Topic; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014363:Tryptamines
D010080:Oxazoles; D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan